The Federal Reserve’s decision to hold rates at 3.5% to 3.75%, paired with a more flexible, data driven tone, has put a fresh spotlight on small-cap stocks that are sensitive to funding costs and monetary policy signals. With the market reading this stance as broadly supportive for risk assets, some smaller companies between $300 million and $2b in market value could see conditions that either ease financing pressure or keep it contained. This article walks through 3 stocks from the Small-Cap Stocks screener that appear positively exposed to this news, helping you assess whether they fit your approach.

SIGA Technologies (SIGA)

Overview: SIGA Technologies is a commercial stage pharmaceutical company focused on health security, with its lead product TPOXX used to treat human smallpox caused by the variola virus. The company is headquartered in New York and targets government and related markets that prepare for biological threats.

Operations: SIGA Technologies generates about US$93.8m in revenue from pharmaceuticals, almost entirely from customers in the United States.

Market Cap: US$309.8m

For investors scanning the Small-Cap Stocks screener, SIGA Technologies stands out as a focused health security company. Its value case rests on a mix of projected high earnings and revenue growth, a P/E that sits slightly above the wider pharmaceuticals industry but well below many peers, and a balance sheet funded entirely through external borrowing. The recent special cash dividend of US$0.60 per share, coupled with high quality earnings, may appeal to income focused investors. However, shrinking profit margins and a larger recent quarterly loss highlight execution and funding risks that cannot be ignored. With the Federal Reserve signaling stable funding conditions for now, the key question is how SIGA uses this window to stabilise margins and justify its growth profile.

SIGA Technologies’ mix of high quality earnings, a special cash dividend and pressure on margins suggests the story may not be as straightforward as it looks, so review the 2 key rewards and 1 important warning sign

Lineage Cell Therapeutics (LCTX)

Overview: Lineage Cell Therapeutics is a clinical stage biotechnology company developing cell replacement therapies, including programs for age related macular degeneration, spinal cord injury, hearing loss, vision loss and Type 1 Diabetes, supported by partnerships with groups such as William Demant Invest and Factor Bioscience.

Operations: Lineage Cell Therapeutics currently generates about US$14.8m in revenue from research and development of therapeutic products.

Market Cap: US$301.7m

Lineage Cell Therapeutics operates at the intersection of regenerative medicine and an aging population. Programs such as OpRegen in eye disease and OPC1 in spinal cord injury are supported by early clinical data and external collaborators. The company is still reporting losses and relies heavily on external funding, so financing risk and pipeline concentration are key considerations. As a result, the broader funding environment and access to capital may be important factors for this business. For investors using the Small-Cap Stocks screener to identify companies with scientific and partnership momentum, Lineage represents a case of high potential alongside clear execution risks that may warrant further research beyond the headlines.

Lineage Cell Therapeutics sits at the junction of aging and regenerative medicine, so get the full picture by reviewing the analyst forecasts for Lineage Cell Therapeutics and see what the market might be missing about its next chapter.

Bank of Marin Bancorp (BMRC)

Overview: Bank of Marin Bancorp is a regional banking group based in Novato, California, offering loans, deposit accounts, cash management, and wealth services to small and mid-sized businesses, nonprofits, and commercial real estate clients, alongside retail customers.

Operations: Bank of Marin Bancorp generates about US$35.3m in revenue from community banking services, all from customers in the United States.

Market Cap: US$412.7m

Bank of Marin Bancorp operates in the small regional bank segment, where a steady Fed funds rate and more predictable monetary policy can matter a lot for funding costs, loan repricing, and net interest margins. At the same time, exposure to Northern California commercial real estate, recent charge offs, and dividends that are not yet well covered by earnings highlight the importance of monitoring credit and payout metrics. For investors scanning banks that could be influenced by stable rates while keeping an eye on risk, Bank of Marin Bancorp may warrant further research.

Bank of Marin Bancorp’s rate sensitive story is still unfolding, with credit quality and dividends pulling in different directions. Review the 2 key rewards and 1 important warning sign to see what could tilt the balance next.

The 3 stocks covered here are only a starting sample of this idea, and the full US$300m to US$2b universe includes 284 more small caps surfaced by the Small-Cap Stocks screener with equally detailed stories and risk profiles. Use Simply Wall St to identify, filter and analyze the specific catalysts, balance sheet traits and earnings narratives that matter to you so you can focus on the highest conviction opportunities within this group.

Take Control of Your Investment Journey

If Bank of Marin Bancorp or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Others Catch On?

Fresh stock ideas do not stay under the radar for long. Spot where breakout momentum could be building and avoid getting caught chasing by positioning early.

• Target resilient cash generators using a curated list of solid balance sheet and fundamentals (48 results) that helps you focus on businesses with room to move while it still matters.
• Ride structural demand shifts by scanning 34 power grid technology and infrastructure stocks positioned around grid upgrades and electrification trends before the crowd fully catches on.
• Position ahead of commodity sentiment turns with the hand picked 33 elite gold producer stocks that highlights producers investors may overlook while they are still dropping off most radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.